secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001193125-25-036816
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma reports FY2024 revenue $491.7M (+23.5% YoY), guides FY2025 $545-565M
--------------------------------------------------------------------------------

- Q4 net product revenue $141.8M; full-year FIRDAPSE revenue $306M (+18.4%), AGAMREE $46M (new launch).
- GAAP net income $163.9M ($1.31 diluted EPS) vs $71.4M ($0.63) in 2023; non-GAAP net income $276.3M ($2.21 diluted EPS).
- Cash and equivalents $517.6M at year-end, up 276% from $137.6M a year ago.
- Full year 2025 revenue guidance set at $545-565M, reflecting continued growth momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/0001193125-25-036816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/d861503d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-036816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer